NHS announces groundbreaking personalised child cancer treatment
The NHS has announced a groundbreaking new treatment, CAR-T, for children with leukaemia...
List view / Grid view
The NHS has announced a groundbreaking new treatment, CAR-T, for children with leukaemia...
Researchers found that more than one quarter (26 per cent) of patients taking Aimovig 70mg were migraine free after month 15...
The FDA has approved the inclusion of new evidence that Cosentyx significantly slows the progression of joint structural damage..
The FDA has approved Gilenya to treat relapsing multiple sclerosis in children and adolescents age 10 years and older...
Novartis is to invest more than $ 100 million to advance research and development of new antimalarials over the next five years...
Novartis and the Bill & Melinda Gates Foundation have formed an alliance to advance the development of Novartis' drug candidate KDU731...
Sandoz has announced that the FDA has approved and launch of Glatopa as a fully-substitutable, AP-rated generic version of Copaxone for relapsing forms of MS...
The FDA has granted Breakthrough Therapy designation to Promacta for use in combination with standard immunosuppressive therapy for severe aplastic anaemia...
Kisqali receives breakthrough therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with HR+/HER2- advanced or metastatic breast cancer...
Sandoz has announced that its biosimilar pegfilgrastim has been accepted by the EMA for regulatory review...
Novartis has announced long-term study results supporting the positive safety and efficacy of Revolade in adults with chronic/persistent immune thrombocytopenia...
Novartis announces CEO Joseph Jimenez to retire from Novartis in 2018. Vasant Narasimhan appointed CEO, effective February 1, 2018.
Novartis announced that the European Commission approved ribociclib in combination with an aromatase inhibitor for treatment of postmenopausal women with metastatic breast cancer
A patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite has been launched...
After the first half of 2017 biopharma investors are in a position to be exuberant, the threat of US price controls that have overshadowed the sector for a year have largely disappeared...